FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news

What is a Lipschultz Ulcer?
Discussion Acute genital ulcers (AGU) are much less common in sexually-naive women than sexually experienced or active women. The differential diagnosis of AGU is large. For sexually active women Herpes simplex virus is the most common cause. Sexually transmitted infections are also included in this differential. In addition to the pain, AGUs can cause distress for the patient and family as possible sexual abuse must be considered. The differential diagnosis of AGU in non-sexually active women includes: Aphthosis Lipschutz ulcer Idiopathic Autoimmune or inflammatory diseases Behcet disease Bullous pemphigoid Inflammato...
Source: PediatricEducation.org - February 8, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

What Are the Clinical Signs and Symptoms of Congenital Syphilis?
Discussion Syphilis is caused by the spirochete Treponema pallidum. It is a very old disease that despite understanding the organism and readily available treatment, still causes disease. Syphilis is transmitted sexually. According to the Centers for Disease Control, “[i]n 2018, a total of 35,063 cases of [Primary and Secondary] syphilis were reported in the United States, yielding a rate of 10.8 cases per 100,000 population …. This rate represents a 14.9% increase compared with 2017 (9.4 cases per 100,000 population), and a 71.4% increase compared with 2014 (6.3 cases per 100,000 population).” The increa...
Source: PediatricEducation.org - September 28, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

What Are Systemic Disease Causes of Oral Ulcers?
Discussion Oral ulcers are common problems seen by dentists but pediatricians also see them. Usually families have are concerned because they are painful and acute. Ulcers are sometime noticed by the physician and not the family as in the case of herpangina or hand-foot and mouth disease. Chronic or recurrent ulcerations present less commonly and therefore it may be more difficult to determine their etiology. Many of the systemic disease causes of oral ulcers are overall infrequent and/or not common in the pediatric age range. Ulcers can be classified in several ways but acute ulcers are usually painful and last less tha...
Source: PediatricEducation.org - September 21, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Refractory Pemphigus Vulgaris Responded to Plasmapheresis Refractory Pemphigus Vulgaris Responded to Plasmapheresis
This case highlights the importance of plasmapheresis as a useful intervention in patients with pemphigus vulgaris who do not respond to conventional therapy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Rilzabrutinib Shows Positive Results in Phase 2b for Pemphigus Rilzabrutinib Shows Positive Results in Phase 2b for Pemphigus
The primary endpoint was control of disease activity, defined as no new lesions and established lesions beginning to heal.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - July 22, 2020 Category: Internal Medicine Tags: Dermatology News Source Type: news

Pandemic Dictates Reconsideration of Pemphigus Therapy Pandemic Dictates Reconsideration of Pemphigus Therapy
The conventional treatment mainstays for pemphigus are problematic during the COVID-19 pandemic, and a shift in disease management strategy is in order.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 17, 2020 Category: Dermatology Tags: Dermatology News Source Type: news

Relapse With Rituximab More Common in Severe Pemphigus Relapse With Rituximab More Common in Severe Pemphigus
Pemphigus patients with severe disease and those with persistent anti-desmoglein (DSG) antibodies three months after starting treatment with rituximab are more prone to relapse while on the drug, according to a new post hoc analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 25, 2020 Category: Consumer Health News Tags: Medscape Today News Source Type: news

The risk of depression in patients with pemphigus: a nationwide cohort study in Taiwan - Hsu YM, Fang HY, Lin CL, Shieh SH.
Pemphigus is a chronic dermatological disorder caused by an autoimmune response and is associated with a high proportion of comorbidities and fatalities. The aim of this study was to investigate the risk of depression in patients with pemphigus. Data were ... (Source: SafetyLit)
Source: SafetyLit - March 25, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Three local life sciences companies raise nearly $200M in 2019 IPOs
Three area life sciences companies went public in 2019, raising a combined $186 million in IPOs completed during a two-week span in late October and early November. University of Pennsylvania spinout Cabaletta Bio of Philadelphia raised $74.8 million in October, selling 6.8 million shares of common stock at $11 per share. Cabaletta is developing a potential cell therapy treatment for mucosal pemphigus vulgaris, a rare skin disorder that causes painful blis ters and sores on mucous membranes. Founded… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 30, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

Penn uncovers dose of medication more likely to put patients with pemphigus into remission
(University of Pennsylvania School of Medicine) Researchers from Penn compare a lymphoma-dose regimen of rituximab to a rheumatoid arthritis regimen for the treatment of pemphigus. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 11, 2019 Category: International Medicine & Public Health Source Type: news

Phase III PEMPHIX study shows Roche ’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Roche today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). (Source: Roche Media News)
Source: Roche Media News - October 14, 2019 Category: Pharmaceuticals Source Type: news

Phase III PEMPHIX study shows Roche ’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Roche today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). (Source: Roche Investor Update)
Source: Roche Investor Update - October 14, 2019 Category: Pharmaceuticals Source Type: news